Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced first subject enrollment in a Phase I/II clinical study evaluating 225Ac-LNC1011 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The targeted alpha radiotherapeutic leverages actinium-225 (225Ac) conjugated to a PSMA-binding ligand, positioning Dongcheng Pharma in the rapidly expanding radiopharmaceutical oncology market targeting the highly specific prostate cancer antigen PSMA.
U.S./EU IND filing anticipated 2027-2028 pending China safety data; potential for Fast Track designation
Mechanism vs. Standard of Care
Parameter
225Ac-LNC1011
177Lu-PSMA (Pluvicto)
Hormonal/Chemotherapy
Radiation Type
Alpha particles (high LET)
Beta particles (medium LET)
Non-radiopharmaceutical
Tissue Range
50-100 μm (cellular precision)
~2 mm (broader scatter)
Systemic
DNA Damage
Double-strand breaks (irreparable)
Single-strand breaks (repairable)
Variable
Resistance Profile
Active in 177Lu-resistant disease
Resistance emerges after multiple cycles
Cross-resistance common
Toxicity
Myelosuppression, xerostomia (manageable)
Similar profile; cumulative
Castration resistance, neuropathy
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical development timelines, radiopharmaceutical manufacturing, and competitive positioning for 225Ac-LNC1011. Actual results may differ due to isotope supply constraints, regulatory requirements, and trial outcomes in the radioligand therapy space.-Fineline Info & Tech
By Fineline Cube